文献速递糖尿病

罗沙司他激活缺氧诱导因子通路改善男性原代肌管糖代谢

Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.
PubMed 文献 · Diabetologia · 2024-05-30

研究用正常糖耐量(NGT)男性(n=5)和2型糖尿病男性(n=8)的原代骨骼肌管,观察罗沙司他对糖代谢的影响。罗沙司他稳定HIF1α并诱导靶基因,增加糖酵解、抑制线粒体呼吸,且在2型糖尿病肌管中增强胰岛素刺激的糖原合成。

要点

  • 罗沙司他稳定肌管核内HIF1α并诱导GLUT1、HK2、MCT4等HIF靶基因。
  • 罗沙司他使NGT肌管糖酵解速率增加1.4倍(p=0.0370),2型糖尿病肌管增加1.7倍(p=0.0044)。
  • 罗沙司他预处理增强2型糖尿病肌管胰岛素刺激的糖原合成(p=0.0345)。

核心结论

  • 罗沙司他在原代人类肌管中增加糖酵解并抑制线粒体呼吸,与糖尿病状态无关。
  • 罗沙司他可能改善2型糖尿病供者肌管中胰岛素对糖原合成的作用。

研究设计与样本

  • 原代骨骼肌细胞培养,来自正常糖耐量男性(n=5)或2型糖尿病男性(n=8)的股外侧肌活检。
  • 肌管用罗沙司他处理,用定量实时PCR检测HIF靶基因表达,用放射性示踪剂检测葡萄糖摄取和糖原合成,用Seahorse分析仪测糖酵解和线粒体呼吸速率。

主要发现

  • 罗沙司他稳定人肌管核内HIF1α蛋白表达。
  • 罗沙司他诱导NGT供者肌管中GLUT1(又称SLC2A1)、HK2、MCT4(又称SLC16A4)和HIF-P4H-2(又称PHD2或EGLN1)的HIF靶基因mRNA,2型糖尿病供者肌管反应减弱。
  • LDHA、PDK1和GBE1的mRNA在NGT和2型糖尿病供者肌管中诱导程度相似。
  • 罗沙司他使NGT男性肌管糖酵解速率增加1.4倍(p=0.0370),使2型糖尿病供者肌管增加1.7倍(p=0.0044),组间无差异(p=0.1391)。
  • 罗沙司他使两组 basal 线粒体呼吸均降低(p<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Hypoxia-inducible factor prolyl 4-hydroxylase (HIF-P4H) enzymes regulate adaptive cellular responses to low oxygen concentrations. Inhibition of HIF-P4Hs leads to stabilisation of hypoxia-inducible factors (HIFs) and activation of the HIF pathway affecting multiple biological processes to rescue cells from hypoxia. As evidence from animal models suggests that HIF-P4H inhibitors could be used to treat metabolic disorders associated with insulin resistance, we examined whether roxadustat, an HIF-P4H inhibitor approved for the treatment of renal anaemia, would have an effect on glucose metabolism in primary human myotubes. METHODS: Primary skeletal muscle cell cultures, established from biopsies of vastus lateralis muscle from men with normal glucose tolerance (NGT) (n=5) or type 2 diabetes (n=8), were treated with roxadustat. Induction of HIF target gene expression was detected with quantitative real-time PCR. Glucose uptake and glycogen synthesis were investigated with radioactive tracers. Glycolysis and mitochondrial respiration rates were measured with a Seahorse analyser. RESULTS: Exposure to roxadustat stabilised nuclear HIF1α protein expression in human myotubes. Treatment with roxadustat led to induction of HIF target gene mRNAs for GLUT1 (also known as SLC2A1), HK2, MCT4 (also known as SLC16A4) and HIF-P4H-2 (also known as PHD2 or EGLN1) in myotubes from donors with NGT, with a blunted response in myotubes from donors with type 2 diabetes. mRNAs for LDHA, PDK1 and GBE1 were induced to a similar degree in myotubes from donors with NGT or type 2 diabetes. Exposure of myotubes to roxadustat led to a 1.4-fold increase in glycolytic rate in myotubes from men with NGT (p=0.0370) and a 1.7-fold increase in myotubes from donors with type 2 diabetes (p=0.0044), with no difference between the groups (p=0.1391). Exposure to roxadustat led to a reduction in basal mitochondrial respiration in both groups (p<0.01). Basal glucose uptake rates were similar in myotubes from donors with NGT (20.2 ± 2.7 pmol mg-1 min-1) and type 2 diabetes (25.3 ± 4.4 pmol mg-1 min-1, p=0.4205). Treatment with roxadustat enhanced insulin-stimulated glucose uptake in myotubes from donors with NGT (1.4-fold vs insulin-only condition, p=0.0023). The basal rate of glucose incorporation into glycogen was lower in myotubes from donors with NGT (233 ± 12.4 nmol g-1 h-1) than in myotubes from donors with type 2 diabetes (360 ± 40.3 nmol g-1 h-1, p=0.0344). Insulin increased glycogen synthesis by 1.9-fold (p=0.0025) in myotubes from donors with NGT, whereas roxadustat did not affect their basal or insulin-stimulated glycogen synthesis. Insulin increased glycogen synthesis by 1.7-fold (p=0.0031) in myotubes from donors with type 2 diabetes. While basal glycogen synthesis was unaffected by roxadustat, pretreatment with roxadustat enhanced insulin-stimulated glycogen synthesis in myotubes from donors with type 2 diabetes (p=0.0345). CONCLUSIONS/INTERPRETATION: Roxadustat increases glycolysis and inhibits mitochondrial respiration in primary human myotubes regardless of diabetes status. Roxadustat may also improve insulin action on glycogen synthesis in myotubes from donors with type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Mäkinen S, Sree S, Ala-Nisula T, et al. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men. Diabetologia. 2024. PMID: 38814443. doi:10.1007/s00125-024-06185-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。